Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Gynecologic Cancer Gynecologic Cancer for March/April 2020 Metastatic cancer linked to worse outcomes of COVID-19, Update confirms survival benefit with trastuzumab in uterine serous carcinoma, Survey reveals gender pay discrepancies among gyn-oncs, Most endometrial cancers treated with minimally invasive procedures, Cancer prevalence among COVID-19 patients may be higher than previously reported, More must reads Gynecologic Cancer for January/February 2020 SOLO3: Olaparib outperforms chemo in heavily pretreated ovarian cancer, Variants in common genes linked to endometrial cancer risk , Proteogenomics provides molecular insights into endometrial carcinoma, IFN-activated monocytes show early promise for ovarian cancer, Vaccinating most girls could eliminate cervical cancer within a century, More must readsGynecologic Cancer for November/December 2019 Fertility-sparing surgery is safe for most with epithelial ovarian cancer, Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancer, In recurrent ovarian cancer, secondary surgery does not extend survival, Surgical Staging Improves Cervical Cancer Outcomes, Sentinel node biopsy safe for women with vulval cancer, More must readsGynecologic Cancer for September/October 2019 Pilot Program Benefits Gynecologic Cancer Patients With Malignant Bowel Obstruction, Veliparib improves PFS in high-grade serous epithelial ovarian cancer, PRIMA study: Niraparib maintenance improves PFS in advanced OC, PAOLA-1/ENGOT-ov25 trial: PARP inhibitor for maintenance improves PFS in advanced ovarian cancer, Closure of women’s health clinics may negatively impact cervical cancer outcomes, More must readsGynecologic Cancer for July/August 2019 Perceived discrimination linked to delay in ovarian cancer diagnosis for black women, Pretreatment CT data may help predict immunotherapy benefit in ovarian cancer, Ovarian Cancer Diagnosed and Treated Earlier Under ACA, Benefit of chemo + RT for high-risk endometrial cancer increases with time, Patient-Provider Survivorship Communication Gaps Persist, More must readsPages« first 1 2 3 4 5 6 last »
